Status:

NOT_YET_RECRUITING

A Proof of Concept (PoC), Randomized, Controlled Study to Validate the Algorithm and Evaluate the Accuracy, Safety and Pain Level of the Smartest-AE in Comparison to Self-measure Blood Glucose Levels

Lead Sponsor:

Smartest Technologies

Collaborating Sponsors:

Israel Innovation Authority

Conditions:

Diabetes Mellitus

Gestational Diabetes Mellitus (GDM)

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The study is conducted in Israel so plain language for the study is exist in Hebrew only

Detailed Description

Protocol Title: A Proof of Concept (PoC), Randomized, Controlled study to validate the algorithm and evaluate the accuracy, safety and pain level of the Smartest-AE in comparison to self-measure Bloo...

Eligibility Criteria

Inclusion

  • Man or Woman, 18 through 80 years of age
  • Diagnosed with either:
  • Group 1: Type I/II Diabetes Melitus/ GDM who regularly prick his/her fingers to monitor blood glucose levels or,
  • Group 2: High risk individuals who do not typically engage in finger pricking but are at high risk of developing prediabetes or diabetes due to one of the following various risk factors:
  • BMI \> 25
  • Age 45 or older
  • Have a parent or sibling with type 2 diabetes
  • Have ever had gestational diabetes
  • Hypercholesterolemia - according to blood level and\\or using medication for lowering cholesterol
  • Dyslipidemia- according to blood level and\\or using medication for lowering lipids
  • Or any other risk factor according to the staff's discretion
  • Able to self-test using a glucose level device
  • Subject is willing and able to comply with protocol requirements and has provided a signed informed consent form (ICF)

Exclusion

  • 1\. Subject suffers from neuropathy, chronic pains, pain diseases, impaired sensation in the fingers\' area 2. Subject diagnosed with dementia 3. Subject diagnosed with major psychiatric disorders 4. Subject use Narcotics or Analgesics, chronically or at the time of enrollment to the study and up to 4 hours prior to first test of the study 5. Any other medical condition that is considered not eligible by the medical team members 6. Subject Is not capable to report pain levels, objectively 7. Participation in an interventional study at the time of enrollment to this study.

Key Trial Info

Start Date :

September 20 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 15 2025

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06587087

Start Date

September 20 2024

End Date

February 15 2025

Last Update

September 19 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The BARUCH PADEH Medical Center, Poriya

Poria – Neve Oved, The Lower Galilee, Israel, 15208